Quantitative Solutions is a leading scientific consultancy to the pharmaceutical and biotech industry. QS develops quantitative models of clinical PK, efficacy and safety data to enable better drug development decisions, including: dose selection, trial design, in-licensing drug evaluation, and more. QS combines the rigor of pharmacokinetic/ pharmacodynamic modeling with the richness of publicly available clinical trial data to derive insights regarding specific development programs/trials in the context of the competitive landscape. Quantitative is based in California and has offices in US and Europe.
GVK Biosciences entered a strategic collaboration with Quantitative Solutions (QS) to develop and market clinical trial outcome databases. The databases capture summary level data for the clinical safety and efficacy outcomes from publicly available data sources.
GVK Biosciences will distribute globally the existing QS databases in five indications including Rheumatoid Arthritis & Psoriasis, Chronic HCV, Neuropathic Pain, Osteoporosis (postmenopausal) and Major Depression immediately. GVK BIO and QS plan to jointly develop and market additional databases in Dyslipidemia, Schizophrenia, Alzheimer’s, and other indications shortly. The Clinical Trial Outcome Databases are designed to assist drug development teams conduct comparative efficacy and safety analysis, link/scale biomarkers to clinical outcomes, predict/improve trial outcome, and develop product differentiation strategies. The databases will be supported by customization and modeling & simulation consulting services provided by GVK BIO and QS, respectively, to ensure maximum flexibility and benefits to the clients. |
|
